News & Events
News & Events
Institut Pasteur Korea and KDB Bank seek cooperation for the nurturing of bio start-ups
2021-07-27
Institut Pasteur Korea and KDB Bank seek cooperation for the nurturing of bio start-ups
On July 9th, Dr. Youngmee Jee, CEO of Institut Pasteur Korea (IPK), invited venture & startup investment experts from KDB Bank to seek cooperation to nurture five bio companies that IPK supports.
Key stakeholders associated with KDB Bank’s investment attraction, including Byungdong Jang, Vice President of Innovation Growth Finance Division, and Wooksang Jung, Head of NextRound, attended the meeting and shared their thoughts.
Participants were introduced to major research areas and core technologies of the five bio venture companies* (hereinafter referred to as resident companies) participating in the Bio Core Facility Establishment Project of IPK, then looked around the startup platforms within the institute where each company has moved in and conducts research and management activities. Next, they discussed about KDB Bank's investment program, such as “NextRound,” which can expedite investment attraction of the resident companies.
* CT Cells Co., Ltd., CellenGene Co., Ltd., CellapeuticsBio Co., Ltd., iPS BIO Co., Ltd., AevisBio Co., Ltd.
.png)
Dr. Jee said, “With the help of KDB Bank's extensive investment network and expertise in nurturing startups, I hope that resident companies with competitive research and technology capabilities in the field of therapeutics development will be able to establish a stable financial basis to pursue the R&D strategies according to their mid- to long-term business plans.”
IPK has been carrying out the Bio Core Facility Establishment Project supported by the Ministry of Science and ICT since 2017. Utilizing the world-class R&D infrastructure for drug discovery and startup incubation expertise, IPK has provided multi-faceted support for the bio-venture companies to gain strong and global competitive edges. As a result of the previous project phase of 2018-2020, five resident companies achieved 2 cases of technology transfer, 350 million KRW in royalty collection, 9 cases and 6 cases each for patent application and registration, investment attraction of 100.8 billion KRW, and creation of 141 job positions.
Key stakeholders associated with KDB Bank’s investment attraction, including Byungdong Jang, Vice President of Innovation Growth Finance Division, and Wooksang Jung, Head of NextRound, attended the meeting and shared their thoughts.
Participants were introduced to major research areas and core technologies of the five bio venture companies* (hereinafter referred to as resident companies) participating in the Bio Core Facility Establishment Project of IPK, then looked around the startup platforms within the institute where each company has moved in and conducts research and management activities. Next, they discussed about KDB Bank's investment program, such as “NextRound,” which can expedite investment attraction of the resident companies.
* CT Cells Co., Ltd., CellenGene Co., Ltd., CellapeuticsBio Co., Ltd., iPS BIO Co., Ltd., AevisBio Co., Ltd.
Dr. Jee said, “With the help of KDB Bank's extensive investment network and expertise in nurturing startups, I hope that resident companies with competitive research and technology capabilities in the field of therapeutics development will be able to establish a stable financial basis to pursue the R&D strategies according to their mid- to long-term business plans.”
IPK has been carrying out the Bio Core Facility Establishment Project supported by the Ministry of Science and ICT since 2017. Utilizing the world-class R&D infrastructure for drug discovery and startup incubation expertise, IPK has provided multi-faceted support for the bio-venture companies to gain strong and global competitive edges. As a result of the previous project phase of 2018-2020, five resident companies achieved 2 cases of technology transfer, 350 million KRW in royalty collection, 9 cases and 6 cases each for patent application and registration, investment attraction of 100.8 billion KRW, and creation of 141 job positions.